Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use NUFYMCO safely and effectively. See full prescribing information for NUFYMCO. NUFYMCOTM (ranibizumab-leyk) injection, for intravitreal useInitial U.S. Approval: 2025NUFYMCO (ranibizumab-leyk) is biosimilar* to LUCENTIS® (ranibizumab injection).
Medication labelWhy this: Advisory · dailymed-prescription
NUFYMCO is indicated for the treatment of patients with:
- generic_name
- ranibizumab-leyk
- product_names
- ranibizumab-leyk
- ndc
- 70710-2172, 70710-2172-1, 70710-2173, 70710-2173-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en